2 June 2016
SpeeDx establishes European subsidiary
The establishment of a European subsidiary company, SpeeDx Limited, headquartered in the London Bioscience Innovation Centre, will support the future...
20 April 2016
ResistancePlus™ MG featured in Medical Laboratory Observer
Dr. Elisa Mokany, SpeeDx’ co-founder and VP of R&D, is featured in an editorial article on Mycoplasma genitalium. The article...
8 April 2016
SpeeDx to Feature PlexPCR® and ResistancePlus® Tests on M. genitalium at ECCMID
Sydney, Australia (April 8, 2016) – SpeeDx Pty, Ltd. today announced that it will feature its PlexPCR® for detection of infectious...
21 March 2016
SpeeDx Announces Distribution Agreement for PlexPCR® and ResistancePlus® Molecular Diagnostics Products with Goffin Molecular Technologies
– Goffin’s distribution channels will allow broader availability and accessibility of SpeeDx diagnostics in the Benelux market – SYDNEY, AUSTRALIA–(March 21,...
1 December 2015
SpeeDx is featured in Austrade’s Success Stories
Austrade’s Success Stories article highlights our focus in tackling the growing threat of antimicrobial resistance using precision medicine. SpeeDx develops...
10 July 2015
SpeeDx is Featured in Genomeweb Article
Genomeweb highlights the launch of SpeeDx’ STI and antimicrobial resistance test. During the interview, Colin Denver – the Vice President...